Rhythm Pharmaceuticals, Inc. Common Stock RYTM
i
Market dataready · fetched 2026-11-12T00:51:09.523Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:11:19.59972103Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T00:51:09.123449+00:00
Rhythm Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 125.99 | 88.1% | 14.9% | 101.64 | 71.1% | 9.7% |
| 25Δ | 121.51 | 76.6% | 11.1% | 104.85 | 59.1% | 7.0% |
| 30Δ | 118.86 | 73.2% | 9.2% | 106.31 | 56.4% | 6.0% |
| 35Δ | 117.09 | 74.3% | 8.1% | 107.69 | 54.1% | 5.1% |
| 40Δ | 115.31 | 75.4% | 7.1% | 109.06 | 51.8% | 4.2% |
| 45Δ | 113.61 | 75.2% | 6.1% | 110.37 | 50.3% | 3.4% |
| 50Δ | 111.93 | 74.7% | 5.3% | 111.52 | 50.6% | 3.0% |
| 55Δ | 110.25 | 74.2% | 4.4% | 112.68 | 50.8% | 2.6% |
| 60Δ | 108.55 | 74.5% | 3.7% | 113.83 | 51.0% | 2.1% |
| 65Δ | 106.86 | 74.8% | 3.1% | 114.98 | 51.3% | 1.7% |
| 70Δ | 105.16 | 75.1% | 2.5% | 116.00 | 48.6% | 1.4% |
| 75Δ | 102.73 | 79.5% | 2.1% | 117.01 | 45.9% | 1.1% |
| 80Δ | 100.23 | 84.2% | 1.7% | 118.03 | 43.1% | 0.8% |
20Δ
- Pseudo strike
- 125.99
- IV
- 88.1%
- B/E move
- 14.9%
- Pseudo strike
- 101.64
- IV
- 71.1%
- B/E move
- 9.7%
25Δ
- Pseudo strike
- 121.51
- IV
- 76.6%
- B/E move
- 11.1%
- Pseudo strike
- 104.85
- IV
- 59.1%
- B/E move
- 7.0%
30Δ
- Pseudo strike
- 118.86
- IV
- 73.2%
- B/E move
- 9.2%
- Pseudo strike
- 106.31
- IV
- 56.4%
- B/E move
- 6.0%
35Δ
- Pseudo strike
- 117.09
- IV
- 74.3%
- B/E move
- 8.1%
- Pseudo strike
- 107.69
- IV
- 54.1%
- B/E move
- 5.1%
40Δ
- Pseudo strike
- 115.31
- IV
- 75.4%
- B/E move
- 7.1%
- Pseudo strike
- 109.06
- IV
- 51.8%
- B/E move
- 4.2%
45Δ
- Pseudo strike
- 113.61
- IV
- 75.2%
- B/E move
- 6.1%
- Pseudo strike
- 110.37
- IV
- 50.3%
- B/E move
- 3.4%
50Δ
- Pseudo strike
- 111.93
- IV
- 74.7%
- B/E move
- 5.3%
- Pseudo strike
- 111.52
- IV
- 50.6%
- B/E move
- 3.0%
55Δ
- Pseudo strike
- 110.25
- IV
- 74.2%
- B/E move
- 4.4%
- Pseudo strike
- 112.68
- IV
- 50.8%
- B/E move
- 2.6%
60Δ
- Pseudo strike
- 108.55
- IV
- 74.5%
- B/E move
- 3.7%
- Pseudo strike
- 113.83
- IV
- 51.0%
- B/E move
- 2.1%
65Δ
- Pseudo strike
- 106.86
- IV
- 74.8%
- B/E move
- 3.1%
- Pseudo strike
- 114.98
- IV
- 51.3%
- B/E move
- 1.7%
70Δ
- Pseudo strike
- 105.16
- IV
- 75.1%
- B/E move
- 2.5%
- Pseudo strike
- 116.00
- IV
- 48.6%
- B/E move
- 1.4%
75Δ
- Pseudo strike
- 102.73
- IV
- 79.5%
- B/E move
- 2.1%
- Pseudo strike
- 117.01
- IV
- 45.9%
- B/E move
- 1.1%
80Δ
- Pseudo strike
- 100.23
- IV
- 84.2%
- B/E move
- 1.7%
- Pseudo strike
- 118.03
- IV
- 43.1%
- B/E move
- 0.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 42.32% | |
| 43.68% | |
| 45.28% | |
| 46.76% | |
| 46.44% | |
| 48.29% | |
| 46.03% | |
| 45.77% | |
| 45.40% | |
| 47.42% |
Biotechnology
RZLT
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City,…
More →SABS
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in…
More →SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
More →SEPN
Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. The company combines…
More →SGMT
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases, particularly non-alcoholic…
More →SION
Description unavailable
More →